A Phase 2 interventional study of Upadacitinib and Placebo in Hidradenitis Suppurativa (HS), sponsored by AbbVie. Completed at 26 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-02-06.
Sponsored by AbbVie · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Hidradenitis Suppurativa by AbbVie — 2 open to participants now, 5 under way, 2 of them phase 3. Hidradenitis Suppurativa · AbbVie.
Among the 18 studies in Hidradenitis Suppurativa by AbbVie, this one is the 9th largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2020, is one of 4 in phase 2, and was the 13th registered.
285 studies on the registry are indexed under Hidradenitis Suppurativa; 88 are open to participants now.
Browse Hidradenitis Suppurativa studies →2 of the 18 studies in Hidradenitis Suppurativa by AbbVie are open now, in 12 countries. Recruiting first, the newest first:
AbbVie · Sites in Argentina, Canada, Colombia and 15 more countries
Ages 12+
AbbVie · Sites in United States
Ages 18–75
By country, each count listing its studies:
Of the 61 Hidradenitis Suppurativa studies recruiting now, 33 (54%) set no upper age limit and 17 (28%) stop at 75 or younger; 13 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 1 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 68 is above the median of 45 across 200 interventional studies indexed under Hidradenitis Suppurativa.
Median enrollment 243 across the 11 interventional studies, 106 across the 6 observational. Of the 12 that completed or were terminated, 8 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
3 of the studies in Hidradenitis Suppurativa by AbbVie that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06468228Phase 3AbbVieA Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | 2026-12 |
| NCT06524635AbbVieA Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab | 2027-02 |
| NCT07136467AbbVieA Real World Study to Globally Assess Disease Burden in Adolescent and Adult Participants With Alopecia Areata, Vitiligo, or Hidradenitis Suppurativa | 2027-08 |
Add all 3 to your calendar (.ics) → With an account.
Among the 18 studies in Hidradenitis Suppurativa by AbbVie, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Hidradenitis suppurativa (HS) is an inflammatory skin disease that causes painful lesions in the axilla (underarm), inguinal (groin) and anogenital (anal and genital) regions. This study will evaluate how well upadacitinib compared to placebo (no medicine) works to treat hidradenitis suppurativa in adult participants with moderate to severe disease. The study will assess change in disease signs and symptoms.
Upadacitinib is an investigational drug being developed for the treatment of HS. This study is "double-blinded," which means that neither the trial participants nor the study doctors will know who will be given study drug and who will receive placebo (no medicine). Participants are randomly (by chance) put into 1 of 2 groups, called treatment arms. They are randomized in a 2 to 1 ratio meaning more participants have a chance to receive upadacitinib compared to placebo.
Participants will undergo approximately 35-days of screening followed by a 48-week treatment period and a 30-day follow-up visit after the last dose of study drug for a total study duration of up to 57 weeks. The treatment period will consist of a 12-week placebo-controlled, double-blind period (Period 1) and a 36-week blinded extension period (Period 2).
There may be a higher burden for participants in this trial compared to their standard of care. Participants will attend visits every other week, once a month, or once every 2 months during the course of the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
-History of active skin disease (other than HS) that could interfere with assessment of HS, including skin infections requiring systemic treatment within 4 weeks of the Baseline visit.
Participants will receive 30 mg upadacitinib orally once a day for 12 weeks (Period 1) followed by 30 mg upadacitinib orally once a day for 36 weeks (Period 2).
Drug: Upadacitinib
Participants will receive matching placebo orally once a day for 12 weeks (Period 1) followed by 15 mg upadacitinib orally once a day for 36 weeks (Period 2).
Drug: Upadacitinib · Drug: Placebo
Tablet; Oral
Also known as: RINVOQ
Tablet; Oral
Percentage of Participants Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 12
HiSCR is defined as at least a 50% reduction in the total abscess and inflammatory nodule (AN) count with no increase in abscess count and no increase in draining fistula count relative to Baseline.
Time frame: Baseline and Week 12
Percentage of Participants Achieving PGA Skin Pain Numeric Rating Scale 30 (NRS30) Response at Week 12 Among Participants With Baseline NRS ≥ 3
The Patient's Global Assessment (PGA) of Skin Pain Numeric Rating Scale (NRS) was used to assess the worst skin pain due to HS. Participants were asked to rate their worst skin pain in the last 24 hours on an 11-point numerical rating scale ranging from 0 (no skin pain) to 10 (skin pain as bad as you can imagine) on a daily basis using an electronic diary. The weekly average score was calculated based on the daily scores from the 7 days prior to the visit (with non-missing values in 4 or more days of the 7 day period). NRS30 is defined as the percentage of participants who achieved at least a 30% reduction and at least 1 unit reduction from Baseline in the PGA of skin pain NRS in participants with Baseline skin pain NRS ≥ 3.
Time frame: Baseline and Week 12
Participants were enrolled at 21 study sites in 3 countries (Canada, Japan, and United States/Puerto Rico).
| Milestone | Placebo / Upadacitinib 15 mg | Upadacitinib 30 mg |
|---|---|---|
| Started | 21 | 47 |
| Received study drug | 21 | 47 |
| Completed | 19 | 41 |
| Not completed | 2 | 6 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 2 |
| Withdrew: Lost to follow-up | 0 | 2 |
| Withdrew: Lack of efficacy | 0 | 1 |
| Withdrew: Other | 0 | 1 |
| Milestone | Placebo / Upadacitinib 15 mg | Upadacitinib 30 mg |
|---|---|---|
| Started | 19 | 41 |
| Completed | 14 | 31 |
| Not completed | 5 | 10 |
| Withdrew: Withdrawal by subject | 2 | 5 |
| Withdrew: Lost to follow-up | 1 | 2 |
| Withdrew: Lack of efficacy | 2 | 3 |
HiSCR is defined as at least a 50% reduction in the total abscess and inflammatory nodule (AN) count with no increase in abscess count and no increase in draining fistula count relative to Baseline.
| percentage of participants | Placebo | Upadacitinib 30 mg |
|---|---|---|
| Percentage of Participants Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 12 | 23.8 (5.6 to 42.0) | 38.3 (24.4 to 52.2) |
The Patient's Global Assessment (PGA) of Skin Pain Numeric Rating Scale (NRS) was used to assess the worst skin pain due to HS. Participants were asked to rate their worst skin pain in the last 24 hours on an 11-point numerical rating scale ranging from 0 (no skin pain) to 10 (skin pain as bad as you can imagine) on a daily basis using an electronic diary. The weekly average score was calculated based on the daily scores from the 7 days prior to the visit (with non-missing values in 4 or more days of the 7 day period). NRS30 is defined as the percentage of participants who achieved at least a 30% reduction and at least 1 unit reduction from Baseline in the PGA of skin pain NRS in participants with Baseline skin pain NRS ≥ 3.
| percentage of participants | Placebo | Upadacitinib 30 mg |
|---|---|---|
| Percentage of Participants Achieving PGA Skin Pain Numeric Rating Scale 30 (NRS30) Response at Week 12 Among Participants With Baseline NRS ≥ 3 | 33.3 (6.7 to 60.0) | 36.4 (20.0 to 52.8) |
Collected over Period 1: From first dose of study drug up to the first dose of study drug during Period 2 (12 weeks). Period 2: From first dose of study drug in Period 2 up to 30 days after the last dose of study drug (maximum of 40 weeks).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Period 1: Placebo | 0/21 (0%) | 0/21 (0%) | 6/21 (28.6%) |
| Period 1: Upadacitinib 30 mg | 0/47 (0%) | 3/47 (6.4%) | 12/47 (25.5%) |
| Period 2: Upadacitinib 15 mg | 0/19 (0%) | 0/19 (0%) | 10/19 (52.6%) |
| Period 2: Upadacitinib 30 mg | 0/41 (0%) | 5/41 (12.2%) | 12/41 (29.3%) |
| Event | Period 1: Placebo | Period 1: Upadacitinib 30 mg | Period 2: Upadacitinib 15 mg | Period 2: Upadacitinib 30 mg |
|---|---|---|---|---|
| CHOLECYSTITISHepatobiliary disorders | 0/21 | 0/47 | 0/19 | 1/41 |
| CELLULITISInfections and infestations | 0/21 | 0/47 | 0/19 | 1/41 |
| ADJUSTMENT DISORDERPsychiatric disorders | 0/21 | 0/47 | 0/19 | 1/41 |
| DEPRESSIONPsychiatric disorders | 0/21 | 0/47 | 0/19 | 1/41 |
| SUICIDAL BEHAVIOURPsychiatric disorders | 0/21 | 0/47 | 0/19 | 1/41 |
| SUICIDAL IDEATIONPsychiatric disorders | 0/21 | 0/47 | 0/19 | 1/41 |
| SKIN PLAQUESkin and subcutaneous tissue disorders | 0/21 | 0/47 | 0/19 | 1/41 |
| HYPOTENSIONVascular disorders | 0/21 | 0/47 | 0/19 | 1/41 |
| COVID-19 PNEUMONIAInfections and infestations | 0/21 | 1/47 | 0/19 | 0/41 |
| ACUTE RESPIRATORY FAILURERespiratory, thoracic and mediastinal disorders | 0/21 | 1/47 | 0/19 | 0/41 |
| Event | Period 1: Placebo | Period 1: Upadacitinib 30 mg | Period 2: Upadacitinib 15 mg | Period 2: Upadacitinib 30 mg |
|---|---|---|---|---|
| HIDRADENITISSkin and subcutaneous tissue disorders | 0/21 | 0/47 | 3/19 | 3/41 |
| DERMATITISSkin and subcutaneous tissue disorders | 3/21 | 0/47 | 1/19 | 0/41 |
| HEADACHENervous system disorders | 0/21 | 5/47 | 2/19 | 2/41 |
| NECK PAINMusculoskeletal and connective tissue disorders | 0/21 | 0/47 | 2/19 | 0/41 |
| CELLULITISInfections and infestations | 2/21 | 0/47 | 0/19 | 0/41 |
| MYALGIAMusculoskeletal and connective tissue disorders | 2/21 | 1/47 | 0/19 | 1/41 |
| ACNESkin and subcutaneous tissue disorders | 1/21 | 1/47 | 0/19 | 3/41 |
| URINARY TRACT INFECTIONInfections and infestations | 0/21 | 3/47 | 0/19 | 2/41 |
| DIZZINESSNervous system disorders | 0/21 | 3/47 | 0/19 | 0/41 |
| ABDOMINAL PAIN UPPERGastrointestinal disorders | 0/21 | 0/47 | 1/19 | 0/41 |
The Intent-to-treat (ITT) population includes all randomized participants
| Age, Continuous(years) | Placebo / Upadacitinib 15 mg | Upadacitinib 30 mg | Total |
|---|---|---|---|
| Mean | 36.6 ± 12.49 | 36.7 ± 11.70 | 36.6 ± 11.85 |
| Age, Customized(Participants) | Placebo / Upadacitinib 15 mg | Upadacitinib 30 mg | Total |
|---|---|---|---|
| < 40 years | 15 | 29 | 44 |
| 40 - < 65 years | 5 | 17 | 22 |
| ≥ 65 years | 1 | 1 | 2 |
| Sex: Female, Male(Participants) | Placebo / Upadacitinib 15 mg | Upadacitinib 30 mg | Total |
|---|---|---|---|
| Female | 16 | 37 | 53 |
| Male | 5 | 10 | 15 |
| Ethnicity (NIH/OMB)(Participants) | Placebo / Upadacitinib 15 mg | Upadacitinib 30 mg | Total |
|---|---|---|---|
| Hispanic or Latino | 5 | 9 | 14 |
| Not Hispanic or Latino | 16 | 38 | 54 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo / Upadacitinib 15 mg | Upadacitinib 30 mg | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 |
| Asian | 3 | 3 | 6 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 7 | 12 | 19 |
| White | 11 | 30 | 41 |
| More than one race | 0 | 1 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Prior Exposure to Tumor Necrosis Factor (TNF) Antagonists(Participants) | Placebo / Upadacitinib 15 mg | Upadacitinib 30 mg | Total |
|---|---|---|---|
| Yes | 6 | 12 | 18 |
| No | 15 | 35 | 50 |
| Hurley Stage(Participants) | Placebo / Upadacitinib 15 mg | Upadacitinib 30 mg | Total |
|---|---|---|---|
| Stage I | 1 | 0 | 1 |
| Stage II | 11 | 24 | 35 |
| Stage III | 9 | 23 | 32 |
| Duration of Hidradenitis Suppurativa (HS) Disease(years) | Placebo / Upadacitinib 15 mg | Upadacitinib 30 mg | Total |
|---|---|---|---|
| Mean | 9.83 ± 4.990 | 11.52 ± 9.401 | 11.00 ± 8.290 |
6 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Data sharing details ↗ · vivli.org
Ran from Jul 2020 to primary completion in Apr 2021, 9 months.
Results were first posted in Feb 2023, 1 year 9 months after primary completion. A results delay was requested in Mar 2022.
Of 44 industry-sponsored phase 2 interventional studies under Hidradenitis Suppurativa, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's 9 months is below that.
Counting every sponsor, half of 54 studies reached it within 15 months; a quarter within 11 and three quarters within 24.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Upadacitinib